Related references
Note: Only part of the references are listed.Global prediction of primary liver cancer incidences and mortality in 2040
Chenxi Li et al.
JOURNAL OF HEPATOLOGY (2023)
MicroRNA-Mediated Drug Repurposing Unveiled Potential Candidate Drugs for Prolactinoma Treatment
Busra Aydin et al.
NEUROENDOCRINOLOGY (2022)
Systems biology based drug repositioning for development of cancer therapy
Beste Turanli et al.
SEMINARS IN CANCER BIOLOGY (2021)
The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours
Pedro Marques et al.
JOURNAL OF NEUROENDOCRINOLOGY (2021)
Artificial intelligence, machine learning, and drug repurposing in cancer
Ziaurrehman Tanoli et al.
EXPERT OPINION ON DRUG DISCOVERY (2021)
Recent Developments in Cancer Systems Biology: Lessons Learned and Future Directions
Kazim Y. Arga et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas
Odelia Cooper et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells
Mari C. Vazquez-Borrego et al.
NEUROENDOCRINOLOGY (2020)
Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab
Mario Caccese et al.
ANTI-CANCER DRUGS (2020)
A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
Mari C. Vazquez-Borrego et al.
CLINICAL CANCER RESEARCH (2020)
Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
Alan Talevi et al.
EXPERT OPINION ON DRUG DISCOVERY (2020)
Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey
Ulf Elbelt et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors
Mari C. Vazquez-Borrego et al.
NEUROENDOCRINOLOGY (2020)
How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020
Jacqueline Trouillas et al.
CANCERS (2020)
Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature-Are We There Yet?
Lydia S. Lamb et al.
CANCERS (2020)
Fast and frugal innovations in response to the COVID-19 pandemic
Matthew Harris et al.
NATURE MEDICINE (2020)
The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)
Maria P. Yavropoulou et al.
ENDOCRINE-RELATED CANCER (2020)
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase
Rosario Pivonello et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review
Kevin Dzobo et al.
CELLS (2020)
Drug Repositioning for P-Glycoprotein Mediated Co-Expression Networks in Colorectal Cancer
Hande Beklen et al.
FRONTIERS IN ONCOLOGY (2020)
Treatment Options for Gonadotroph Tumors: Current State and Perspectives
Mirela Diana Ilie et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions
Tamer N. Jarada et al.
JOURNAL OF CHEMINFORMATICS (2020)
Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19
Tania Islam et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Bexarotene combined with lapatinib for the treatment of Cushing's disease: evidence based on drug repositioning and experimental confirmation
Haoying Yu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Broadening Drug Design and Targets to Tumor Microenvironment? Cancer-Associated Fibroblast Marker Expression in Cancers and Relevance for Survival Outcomes
Kevin Dzobo et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2020)
The role of the tumour microenvironment in the angiogenesis of pituitary tumours
Pedro Marques et al.
ENDOCRINE (2020)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2020)
Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms
Mari C. Vazquez-Borrego et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Epidemiology and Management Challenges in Prolactinomas
Laurent Vroonen et al.
NEUROENDOCRINOLOGY (2019)
Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning
Beste Turanli et al.
EBIOMEDICINE (2019)
Multi-Omic Data Interpretation to Repurpose Subtype Specific Drug Candidates for Breast Cancer
Beste Turanli et al.
FRONTIERS IN GENETICS (2019)
Analysis of Tumor Angiogenesis and Immune Microenvironment in Non-Functional Pituitary Endocrine Tumors
Mizuto Sato et al.
JOURNAL OF CLINICAL MEDICINE (2019)
The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new
Philippe Chanson et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Medical Management of Cushing Disease
Nicholas A. Tritos et al.
NEUROSURGERY CLINICS OF NORTH AMERICA (2019)
Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma
Eva C. Coopmans et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma A Single-Center, Open-Label, 2-Year Randomized Clinical Trial
Rafael L. Batista et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2019)
Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness
Pedro Marques et al.
ENDOCRINE-RELATED CANCER (2019)
Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas
Dongyun Zhang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Apatinib (YN968D1) and Temozolomide in Recurrent Invasive Pituitary Adenoma: Case Report and Literature Review
Yong Wang et al.
WORLD NEUROSURGERY (2019)
Continuous Etomidate Infusion for the Management of Severe Cushing Syndrome: Validation of a Standard Protocol
Ty B. Carroll et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2019)
Drug repurposing: progress, challenges and recommendations
Sudeep Pushpakom et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
Gerald Raverot et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Anti-Cancer Effects of Metformin: Recent Evidences for its Role in Prevention and Treatment of Cancer
Masoumeh Kheirandish et al.
CURRENT DRUG METABOLISM (2018)
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
Ann McCormack et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Management of NFAs: medical treatment
Naomi Even-Zohar et al.
PITUITARY (2018)
Drug Repositioning for Effective Prostate Cancer Treatment
Beste Turanli et al.
FRONTIERS IN PHYSIOLOGY (2018)
A Network-Based Cancer Drug Discovery: From Integrated Multi-Omics Approaches to Precision Medicine
Beste Turanli et al.
CURRENT PHARMACEUTICAL DESIGN (2018)
Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR
Ernesto Sosa-Eroza et al.
ENDOCRINE (2018)
MANAGEMENT OF ENDOCRINE DISEASE Present and future perspectives for medical therapy of nonfunctioning pituitary adenomas
Yona Greenman
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas
Helene Lasolle et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection
Waseem Touma et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2017)
Cushing's disease: pathobiology, diagnosis, and management
Russell R. Lonser et al.
JOURNAL OF NEUROSURGERY (2017)
Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells
Jiayin An et al.
ONCOTARGET (2017)
Transcriptomic-Guided Drug Repositioning Supported by a New Bioinformatics Search Tool: geneXpharma
Beste Turanli et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2017)
The 2017 World Health Organization classification of tumors of the pituitary gland: a summary
M. Beatriz S. Lopes
ACTA NEUROPATHOLOGICA (2017)
Synergistic Inhibition of Delayed Rectifier K+ and Voltage-Gated Na+ Currents by Artemisinin in Pituitary Tumor (GH3) Cells
Edmund Cheung So et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
Tumor microenvironment and therapeutic response
Ting Wu et al.
CANCER LETTERS (2017)
Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status
Vincent Lo Re et al.
AMERICAN JOURNAL OF MEDICINE (2016)
Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds
Roberto Wuerth et al.
DRUG DISCOVERY TODAY (2016)
Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists
Y. Greenman et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
'RE: fine drugs': an interactive dashboard to access drug repurposing opportunities
Soheil Moosavinasab et al.
DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION (2016)
Complications of Cushing's syndrome: state of the art
Rosario Pivonello et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Treating prolactinomas with dopamine agonists: always worth the gamble?
Sean Noronha et al.
ENDOCRINE (2016)
Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management
Fatemeh G. Amlashi et al.
ENDOCRINE (2016)
Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline
Lynnette K. Nieman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients
Eleni Daniel et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Optimal management of non-functioning pituitary adenomas
Yona Greenman et al.
ENDOCRINE (2015)
The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011
Axel Tjornstrand et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs
Joong Sup Shim et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2014)
Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone
Maria Fleseriu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Ketoconazole in Cushing's Disease: Is It Worth a Try?
Frederic Castinetti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Thyrotropin-Secreting Pituitary Adenomas: Outcome of Pituitary Surgery and Irradiation
Elena Malchio et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly: An Endocrine Society Clinical Practice Guideline
Laurence Katznelson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
A. Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Treatment of Cushing's disease: a mechanistic update
Daniel Cuevas-Ramos et al.
JOURNAL OF ENDOCRINOLOGY (2014)
Management of medically refractory prolactinoma
Mark E. Molitch
JOURNAL OF NEURO-ONCOLOGY (2014)
Medical management of Cushing's disease
Nicholas A. Tritos et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures
Qiaonan Duan et al.
NUCLEIC ACIDS RESEARCH (2014)
Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry
Roberto Salvatori et al.
PITUITARY (2014)
Artemisinins: Pharmacological actions beyond anti-malarial
Wanxing Eugene Ho et al.
PHARMACOLOGY & THERAPEUTICS (2014)
DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information
I. Amelio et al.
CELL DEATH & DISEASE (2014)
Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors
Odelia Cooper et al.
ENDOCRINE (2014)
DrugMap Central: an on-line query and visualization tool to facilitate drug repositioning studies
Changhe Fu et al.
BIOINFORMATICS (2013)
National Incidence and Prevalence of TSH-Secreting Pituitary Adenomas in Sweden
Lisa Onnestam et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Medical Treatment of Cushing's Disease
Richard A. Feelders et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy
Maria Fleseriu et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Prevalence and incidence of pituitary adenomas: a population based study in Malta
Mark Gruppetta et al.
PITUITARY (2013)
Pegvisomant and cabergoline combination therapy in acromegaly
I. Bernabeu et al.
PITUITARY (2013)
Repositioning metformin for cancer prevention and treatment
Brendan J. Quinn et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2013)
2013 European Thyroid Association Guidelines for the Diagnosis and Treatment of Thyrotropin-Secreting Pituitary Tumors
P. Beck-Peccoz et al.
EUROPEAN THYROID JOURNAL (2013)
Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug
Hee Sook Lee et al.
BMC SYSTEMS BIOLOGY (2012)
Drug discovery in the age of systems biology: the rise of computational approaches for data integration
Murat Iskar et al.
CURRENT OPINION IN BIOTECHNOLOGY (2012)
Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center
Camille Baudry et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4-and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours
U. Ploeckinger et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review
Veronica A. Preda et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY
A. J. van der Lely et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome
Maria Fleseriu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Artesunate inhibits cell proliferation and decreases growth hormone synthesis and secretion in GH3 cells
Zhi-gang Mao et al.
MOLECULAR BIOLOGY REPORTS (2012)
NCATS launches drug repurposing program
Malorye Allison
NATURE BIOTECHNOLOGY (2012)
A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease
Annamaria Colao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study
Alessandra Fusco et al.
PITUITARY (2012)
Place of Cabergoline in Acromegaly: A Meta-Analysis
Laure Sandret et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
PROMISCUOUS: a database for network-based drug-repositioning
Joachim von Eichborn et al.
NUCLEIC ACIDS RESEARCH (2011)
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Sebastian J. C. M. M. Neggers et al.
PITUITARY (2011)
Incidence of Pituitary Adenomas in Northern Finland in 1992-2007
Antti Raappana et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease
Lucio Vilar et al.
PITUITARY (2010)
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide AutogelA® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
Shlomo Melmed et al.
PITUITARY (2010)
Cushing's disease
Xavier Bertagna et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients
Masami Ono et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
Moises Mercado et al.
CLINICAL ENDOCRINOLOGY (2007)
Medical progress: Acromegaly
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2006)
High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium
Adrian F. Daly et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Advances in the treatment of prolactinomas
Mary P. Gillam et al.
ENDOCRINE REVIEWS (2006)
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Felipe F. Casanueva et al.
CLINICAL ENDOCRINOLOGY (2006)
Quinagolide - a valuable treatment option for hyperprolactinaemia
A Barlier et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Cushing's syndrome during pregnancy: Personal experience and review of the literature
JR Lindsay et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: Comparison with the effectiveness of cabergoline treatment
R Pivonello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Clinical review 166 - Growth hormone receptor antagonists
AF Muller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Drug repositioning: Identifying and developing new uses for existing drugs
TT Ashburn et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy
G Blackhurst et al.
CLINICAL ENDOCRINOLOGY (2002)
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
AJ van der Lely et al.
LANCET (2001)
Share Paper
